Detalles de la búsqueda
1.
Overexpression of TP53 is associated with poor survival, but not with reduced response to hypomethylating agents in older patients with acute myeloid leukaemia.
Br J Haematol
; 178(5): 810-812, 2017 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-27431572
2.
Platelet doubling after the first azacitidine cycle is a promising predictor for response in myelodysplastic syndromes (MDS), chronic myelomonocytic leukaemia (CMML) and acute myeloid leukaemia (AML) patients in the Dutch azacitidine compassionate named patient programme.
Br J Haematol
; 155(5): 599-606, 2011 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-21981697
3.
Effective targeting of primitive AML CD34+ cells by the second-generation proteasome inhibitor carfilzomib.
Br J Haematol
; 171(4): 652-5, 2015 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-25873108
4.
Absence of aberrant myeloid progenitors by flow cytometry is associated with favorable response to azacitidine in higher risk myelodysplastic syndromes.
Cytometry B Clin Cytom
; 2014 Jan 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-24431028
5.
Absence of aberrant myeloid progenitors by flow cytometry is associated with favorable response to azacitidine in higher risk myelodysplastic syndromes.
Cytometry B Clin Cytom
; 86(3): 207-15, 2014 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-24474614
6.
Azacitidine might be beneficial in a subgroup of older AML patients compared to intensive chemotherapy: a single centre retrospective study of 227 consecutive patients.
J Hematol Oncol
; 6: 29, 2013 Apr 16.
Artículo
en Inglés
| MEDLINE | ID: mdl-23587459
Resultados
1 -
6
de 6
1
Próxima >
>>